Literature DB >> 23847328

Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.

Bernhard Mayr1, Rolf Buslei, Marily Theodoropoulou, Günter K Stalla, Michael Buchfelder, Christof Schöfl.   

Abstract

OBJECTIVE: GH-producing pituitary adenomas display two distinct morphological patterns of cytoplasmic GH-containing secretory granules, namely the densely and sparsely granulated somatotroph adenoma subtype. It is unknown whether these morphological variants reflect distinct pathophysiological entities at the molecular level.
METHODS: In 28 GH-producing adenoma tissues from a consecutive set of patients undergoing pituitary surgery for acromegaly, we studied the GH granulation pattern, the expression of somatostatin receptor subtypes (SSTR) as well as the calcium, cAMP and ZAC1 pathways in primary adenoma cell cultures.
RESULTS: The expression of GSP oncogene was similar between densely and sparsely granulated somatotroph adenoma cells. There were no differences in the calcium, cAMP and ZAC1 pathways as well as in their regulation by SSTR agonists. SSTR2 was exclusively expressed in densely but not in sparsely granulated tumours (membrane expression 86 vs 0%; cytoplasmic expression 67 vs 0%). By contrast, expression of SSTR5 was only found in sparsely but not in densely granulated somatotroph adenomas (membrane expression 29 vs 0%; cytoplasmic expression 57 vs 0%).
CONCLUSIONS: Our results indicate that different granulation patterns in GH-producing adenomas do not reflect differences in pathways and factors pivotal for somatotroph differentiation and function. In vitro, the vast majority of both densely and sparsely granulated tumour cells were responsive to SSTR activation at the molecular level. Sparsely granulated adenomas lacking SSTR2, but expressing SSTR5, might be responsive to novel SSTR agonists with increased affinity to SSTR5.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23847328     DOI: 10.1530/EJE-13-0134

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  28 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

2.  A structural and functional acromegaly classification.

Authors:  Daniel Cuevas-Ramos; John D Carmichael; Odelia Cooper; Vivien S Bonert; Arkadiusz Gertych; Adam N Mamelak; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

3.  Growth hormone tumor histological subtypes predict response to surgical and medical therapy.

Authors:  Katja Kiseljak-Vassiliades; Nichole E Carlson; Manuel T Borges; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Janice M Kerr; Margaret E Wierman
Journal:  Endocrine       Date:  2014-08-17       Impact factor: 3.633

4.  Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ming Shen; Qilin Zhang; Wenjuan Liu; Meng Wang; Jingjing Zhu; Zengyi Ma; Wenqiang He; Shiqi Li; Xuefei Shou; Yiming Li; Zhaoyun Zhang; Hongying Ye; Min He; Bin Lu; Zhenwei Yao; Yun Lu; Nidan Qiao; Zhao Ye; Yichao Zhang; Yeping Yang; Yao Zhao; Yongfei Wang
Journal:  Neuroradiology       Date:  2016-08-11       Impact factor: 2.804

Review 5.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 6.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Authors:  Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

8.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

Review 9.  Emerging Histopathological and Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recommendation for Future WHO Classification.

Authors:  W Saeger; S Petersenn; C Schöfl; U J Knappe; M Theodoropoulou; R Buslei; J Honegger
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

10.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.